

VALEANT PHARMACEUTICALS INTERNATIONAL

Form 8-K

November 14, 2003

**Table of Contents**

---

---

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of the earliest event reported): November 13, 2003

---

**Valeant Pharmaceuticals International**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

1-11397  
(Commission File Number)

33-0628076  
(IRS Employer Identification  
No.)

3300 Hyland Avenue  
Costa Mesa, California 92626  
(Address of principal executive offices) (Zip Code)

(714) 545-0100  
(Registrant's telephone number, including area code)

---

---

---

**TABLE OF CONTENTS**

Item 5. Other Events and Regulation FD Disclosure.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

EXHIBIT 99.2

---

**Table of Contents**

**Item 5. Other Events and Regulation FD Disclosure.**

November 13, 2003 Press Release

On November 13, 2003, Valeant Pharmaceuticals International issued a press release announcing its intention to offer, subject to market and other conditions, approximately \$200 million principal amount of Convertible Subordinated Notes due 2010 and approximately \$200 million principal amount of Convertible Subordinated Notes due 2013 (the Notes ) to qualified institutional buyers in an offering exempt from registration pursuant to Rule 144A under the Securities Act of 1933. The November 13, 2003 press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.

November 14, 2003 Press Release

On November 14, 2003, Valeant Pharmaceuticals International issued a press release announcing the pricing of its offering of the Notes. The sale of the Notes is expected to close on November 19, 2003. The November 14, 2003 press release is attached as Exhibit 99.2 to this report and is incorporated herein by this reference.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

(c) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release dated November 13, 2003.
99.2	Press release dated November 14, 2003.

-1-

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 14, 2003

VALEANT PHARMACEUTICALS INTERNATIONAL

-2-

---

**Table of Contents**

**EXHIBIT INDEX**

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
99.1	Press release dated November 13, 2003.
99.2	Press release dated November 14, 2003.